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Abstract
Objective—To identify clinical indicators for success of misoprostol treatment after early
pregnancy failure.
Methods—A total of 473 women with early pregnancy failure received 800 μg of vaginal
misoprostol on treatment day 1. At the follow-up visit on day 3, a second dose was given if expulsion
was incomplete. On day 8, vacuum aspiration was offered if expulsion had not occurred.
Ultrasonography was used as gold standard for success. A Classification and Regression Tree
analysis was undertaken to derive two decision trees for the success of misoprostol treatment on
study days 3 and 8.
Results—Heavy bleeding after the first dose and an open cervical os were identified as clinical
indicators of treatment success on day 3. Treatment success occurred in 84% of women with either
or both indicators. Reporting passage of tissue after a second misoprostol dose and old blood in the
vagina were potential indicators of treatment success or failure on day 8. A woman with either of
these indicators has a 65% chance of treatment success after the second dose. Conversely, a woman
with neither indicator on day 8 has a 94% chance of treatment failure.
Conclusion—Standard clinical findings may be useful as indicators for success or failure of
medical management of early pregnancy failure in settings with limited or no access to
ultrasonography. More research to identify even better indicators is warranted.
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One in four women will experience an early pregnancy failure during her reproductive life
[1]. The current standard of care for early pregnancy failure is surgical management through
vacuum aspiration [2]. Recently, medical management of early pregnancy failure with
misoprostol, a synthetic prostaglandin E1 analogue, has been shown to be effective, safe, and
convenient [3]. It has the same or an even higher acceptability rate as surgical treatment for
early pregnancy loss [4,5].
In most previous research studies, transvaginal ultrasonography was used to verify the
expulsion of the products of conception after medical management with misoprostol. During
follow-up visits if ultrasonography showed a substantial endometrial lining, or if a gestational
sac could still be seen, subjects received a second dose of misoprostol or vacuum aspiration
[3,6]. In this instance ultrasonography enabled clinicians to validate the completion of the
treatment in order to accurately diagnose and treat subjects. However, access to this type of
technology in resource poor settings could limit the use of misoprostol treatment. The purpose
of this study is to identify clinical signs and symptoms that correlate with ultrasound evidence
of completion of expulsion. Quantitative assessment is used to ascertain whether clinical
indicators can be used to guide further treatment when ultrasound is not readily accessible.
Materials and Methods
Data from a multi-center randomized clinical trial on the management of early pregnancy
failure was used. Detailed description of the trial is provided elsewhere [3]. Briefly, 652 women
who had early pregnancy failure in the first trimester (embryo/fetal demise, anembryonic
gestation, incomplete or inevitable spontaneous abortion) were recruited from four university
hospitals. Participants were randomly assigned in a 3:1 ratio to receive medical treatment or
vacuum aspiration. Of the subjects, 94% had anembryonic gestation or embryonic/fetal demise,
and 6% had incomplete or inevitable spontaneous abortion.
The current analysis focused on the 487 subjects who were assigned to receive misoprostol
treatment only. On the first day of the study these women had four 200 μg tablets of misoprostol
(Cytotec; Pfizer, New York, USA) inserted into the posterior fornix through a speculum. On
day 3 the women returned for a follow-up visit with vaginal ultrasonography. If this
examination indicated expulsion of the gestational sac, the subjects were asked to come back
on day 15. If the examination indicated persistence of the gestational sac or an endometrial
lining greater than 30 mm, the women received a second dose of 800 μg of misoprostol
vaginally. On day 8 vaginal ultrasonography was repeated and vacuum aspiration offered if
the gestational sac was visualized. All subjects returned for a follow-up visit on day 15. The
trial was approved by the Institutional Review Boards of participating institutions.
Baseline demographic characteristics of each woman (e.g. age, race) were collected at
enrollment. The women were asked to keep diaries of symptoms such as bleeding, fever, and
temperature for two weeks. The women were given complete physical examinations at follow-
up visits on treatment days 3 and 8. For the current analysis, 28 variables were included as
potential indicators. In addition to those listed in Table 1, baseline characteristics such as
gestational age, parity, type of pregnancy failure, Rh type, vaginal bleeding within 24 hours
prior to treatment, and side effects related to misoprostol treatment (e.g. vomiting, diarrhea,
chills, fever, and headache) were also examined.
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Univariate analyses were performed using SAS 9.1 (Cary, NC, USA) to identify any significant
relationships between indicator variables and misoprostol treatment success on days 3 and 8.
Chi square test and Fisher’s Exact Test were performed.
To obtain an optimal clinical decision rule Classification and Regression Tree (CART) analysis
was used [7]. CART analysis is a nonparametric statistical method that uses an algorithm to
classify observations based on the value of predictor variables. The program first selects a
single predictor variable that best classifies the women in the study population into misoprostol
treatment success or failure subgroups. Subgroups are then split based on the next best
predictors until a decision tree has been derived with several levels [7,8]. Two separate CART
analyses were performed to ascertain the best indicators of misoprostol treatment success on
days 3 and 8.
The optimal clinical decision depends on the ratio of the “cost” of under-treating a woman who
is misclassified as a success versus over-treating a woman misclassified as a failure. Here the
“cost” is a general term for both monetary and non-monetary cost. On day 3 if a woman is
classified as a success she would not undergo an ultrasound or a physical examination on day
8. The error of under-treating on day 3 would mean that the expulsion of a non-viable pregnancy
is not completed. The consequences of under-treatment would include continued bleeding,
pain, and potential emergent care for an incomplete abortion. Consequences of over-treating
on day 3 would include an unnecessary dose of misoprostol and its consequences such as
nausea, pain, or other side effects. In this situation, under-treatment was considered the greater
error. Thus, the ratio of the cost of under-treating versus over-treating a woman was set between
2:1 and 4:1.
Conversely, the weight of error was considered differently for day 8. On day 8, if the expulsion
had not occurred, a dilation and curettage (D&C) would be recommended. Therefore, over-
treatment would be referring a patient to surgical treatment. Because this recommendation
would involve surgical management on all subjects, it was considered a greater error than that
of under-treatment on day 8. The consequences of under-treatment on day 8 would potentially
mean that the miscarriage was not fully treated, which could result in prolonged bleeding and
pain, and potential need for emergency services. Therefore, the ratio of the cost of under-
treating versus over-treating a woman was set between 1:2 and 1:4.
CART produced a regression tree for each cost ratio [7]. Final trees were selected after
considering their interpretability and application in a clinical setting. To assess the sensitivity,
specificity, and positive and negative predictive values, we used ten-fold cross validation. This
method, described by Breiman et al. [7] partitions the data into 10 subsets, and uses all but one
subset at a time to derive classifiers that are each assessed by the one-tenth of the data not used
in its construction. The estimates resulting from the subsets were averaged, giving a single
cross-validated estimate for each of the various measures.
Results
Of the 487 women who received misoprostol treatment, women who were lost to follow-up
(n=2) or had an unknown outcome for day 3 (n=12) were excluded. Success of treatment was
analyzed in the remaining 473 women. Table 1 shows that women had a significantly higher
rate of success on day 3 if they reported to have had heavy bleeding, passed tissue, used codeine,
or had one of the following physical signs: a pool of blood in the vagina, open cervical os,
active bleeding, or tissue at cervical os.
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The regression trees that resulted with the cost ratio of 2:1 and 3:1 were the same for day 3.
This tree was chosen as the final predictor model (Fig. 1). It included two indicators of success
of misoprostol treatment: heavy bleeding after the treatment, and cervical os open. The
sensitivity, specificity, and positive and negative predictive values of this diagnostic algorithm
are estimated by cross validation as 78%, 60%, 84% and 51%, respectively, i.e. 84% of women
who are considered a treatment success according to clinical indicators after first dose can be
confirmed by ultrasonography.
To identify clinical indicators of success among 107 women who received a second dose of
misoprostol, one subject who had an unknown outcome for day 8 was excluded. Table 2
indicates that women had a significantly higher rate of success if they reported to have had
heavy bleeding, passed tissue, used analgesic, or had one of the following physical findings at
the day 8 visit: a pool of blood in the vagina, old blood only in the vagina, or cervical active
bleeding.
The regression trees for misoprostol treatment success on day 8 with cost ratios between 1:2
and 1:4 were identical (Fig. 2). Passing tissue after a second dose and old vaginal blood present
were indicators of treatment success on day 8. The sensitivity, specificity, and positive and
negative predictive values of this diagnostic algorithm are estimated by cross validation as
90%, 34%, 67% and 94%, respectively, i.e. two-thirds of women who report to have passed
tissue or have old blood present in the vagina have completed expulsion. Conversely, 94% of
women who have neither indicators positive are a treatment failure.
The above analyses were repeated for women with only anembryonic gestation or fetal demise.
The results essentially remained the same (not shown).
Discussion
In the last decade, numerous studies have shown that medical treatment with misoprostol for
early pregnancy failure is safe, effective, and convenient [3,6,9]. This treatment is gaining
acceptance by physicians and patients [9,10]. However, confirmation of treatment success and
the decision for further treatment are often based on ultrasonography findings. The widespread
use of this treatment, especially in the developing world, may still be in part dependant on the
availability of a reliable predictive tool that can be used in clinical settings where
ultrasonography is not easily available. Using a CART analysis, we identified two factors –
self-reported heavy bleeding and an open cervical os on day 3 – as potentially useful indicators
of treatment success after the first dose of misoprostol. Approximately 84% of women who
have either indicator positive have had a successful treatment. After a second dose, if a woman
neither reports having passed tissue nor has old blood in the vagina, the treatment fails in 94%
of cases.
Given the relatively low likelihood of treatment success (49%), if a patient has not had heavy
bleeding and the cervical os is closed on day 3, giving a second dose of misoprostol may be
an appropriate choice. These patients account for approximately one-third of our study
population. However, women with either or both indicators positive still have a 16% chance
of having incomplete expulsion at that time. Although expulsion may complete spontaneously
in these women, patients should be counseled that there is a small possibility (< 1%) of infection
or hemorrhage, and that further treatment may still be needed.
Clinical indicators on day 8 have a low positive predictive value (67%), i.e. presence of either
or both indicators does not assure a treatment success. However, these indicators have a high
negative predictive value (94%). Women who have neither passed tissue nor have old blood
in the vagina are very likely to have had a failed treatment. Offering vacuum aspiration may
be appropriate.
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To our knowledge, this is the first study that examines clinical indicators for treatment success
after misoprostol application for early pregnancy failure. However, several limitations in our
study should be acknowledged. First, how well a clinical indicator can predict outcome (i.e.
positive predictive value) partly depends on the success rate of the treatment. This relationship
is a positive correlation. Since the success rate after the first dose of misoprostol was 71% in
our study [3], the positive predictive value on day 3 (84%) appears reasonably good.
Nonetheless, a higher predictive value would be more desirable.
Second, our study tries to identify individual indicators two days after the treatment. The short
interval between the treatment and the follow-up visit could make prediction difficult. For
instance, an open cervical os could indicate that the uterus has responded to the misoprostol
treatment. It would also indicate that the expulsion may not be complete, is in the process of
occurring, or has just been completed. Our data suggest that on day 3, an open os is more likely
to be indicative of a positive uterine response and expulsion may have just been completed.
However, this indicator may not be applicable for later dates.
Third, in the symptom diary, women were asked “how much bleeding have you had in the last
24 hours?” The following choices were given: none, spotting, light, moderate, heavy, and more
than two pads per hour. Heavy bleeding in this study is defined as heavy or more than two pads
per hour. Nonetheless, self-reported heavy bleeding is still a subjective measure. Non-
differential misclassification could reduce the predictive value.
Finally, women who were found to have had complete expulsion on day 3 did not come back
on day 8 in our study. In a setting without ultrasonography it is likely that more women would
be evaluated on day 8, which would change the prevalence of success in the group being tested.
This could change the performance of the indicators on day 8. CART analysis may even select
different indictors in a new group of women. Unfortunately, data from the current study do not
allow us to assess the impact of the above scenario.
Our study shows that clinical indicators can be predictive of success or failure of medical
management with misoprostol for early pregnancy failure. However, these indicators are not
definitive. Ultrasonography is still superior to clinical indictors in diagnosing complete
expulsion of the products of conception. Still, among women who have positive clinical
indicators after the first dose of misoprostol, it would take six ultrasonography examinations
to identify one patient with incomplete expulsion. As most miscarriages can resolve
spontaneously, it remains to be tested whether a precise diagnosis will be able to translate into
substantial gain in resource poor areas. When access to ultrasonography is limited, these
clinical indicators may provide some guidance in the physician’s decision-making for further
treatment. More studies are needed to identify better clinical indicators.
Acknowledgements
The work of this paper is supported by the Intramural Research Program at the National Institute of Child Health and
Human Development, National Institutes of Health, DHHS.
References
1. Alberman, E. Spontaneous abortions: epidemiology. In: Stabile, I.; Grudzinskas, G.; Chard, T., editors.
Spontaneous abortion: diagnosis and treatment. London: Springer-Verlag; 1992. p. 19-20.
2. Creinin M, Schwartz J, Guido R, Pymar H. Early pregnancy failure – current management concepts.
Obstet Gynecol Surv 2001;56:105–13. [PubMed: 11219590]
3. Zhang J, Gilles J, Barnhart K, Creinin M, Westhoff C, Frederick M. Comparison of medical
management with misoprostol and surgical management for early pregnancy failure. N Engl J Med
2005;358:761–9. [PubMed: 16120856]
Robledo et al. Page 5













4. Lee D, Cheung L, Haines C, Chan K, Chung T. Comparison of the psychologic impact and client
satisfaction of surgical treatment with medical treatment of spontaneous abortion: a randomized
controlled trial. Am J Obstet Gynecol 2001;185:953–8. [PubMed: 11641684]
5. Graziosi G, Bruinse H, Reuwer P, Mol B. Women’s preferences for misoprostol in case of early
pregnancy failure. Eur J Obstet Gynecol Reprod Biol 2006;124:184–6. [PubMed: 16026923]
6. Graziosi GC, Bruinse HW, Reuwer PJ, Mol BW. Women’s preferences for misoprostol in case of early
pregnancy failure. Eur J Obstet Gynecol Reprod Bio 2006;124:184–6. [PubMed: 16026923]
7. Breiman, L.; Friedman, JH.; Olshen, RA.; Stone, CJ. Classification and Regression Trees. 2. Pacific
Grove, CA: Wadsworth; 1984.
8. Zhang, H.; Singer, B. Recursive partitioning in the health sciences. New York: Springer-Verlag; 1999.
9. Graziosi GCM, Mol BW, Ankum WM, Bruinse HW. Management of early pregnancy loss. Intl J
Gynecol Obstet 2004;86:337–46.
10. Murchison A, Duff P. Misoprostol for uterine evacuation in patients with early pregnancy failures.
Am J Obstet Gynecol 2004;190:1445–6. [PubMed: 15167864]
Robledo et al. Page 6














Decision tree obtained from Classification and Regression Tree analysis to predict success of
misoprostol treatment on day 3.
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Decision tree obtained from Classification and Regression Tree analysis to predict success of
misoprostol treatment on day 8.
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Table 1
Univariate analysis of clinical indicators for success of misoprostol treatment on day 3
Variables n Success (%) P value
Variables from Symptom Diary: After Dose 1, day 1 to day 3
Heavy Bleeding Ever
 Yes 287 83
 No 183 58 <0.0001
Passed Tissue Ever
 Yes 382 77
 No 88 58 < 0.001
Tired Ever
 Yes 340 74
 No 130 73 0.921
Light Headed Ever
 Yes 217 78
 No 253 69 0.025
Faint Ever
 Yes 29 83
 No 441 73 0.239
Called Doctors Ever
 Yes 87 75
 No 383 73 0.760
Visit Doctors Ever
 Yes 22 73
 No 448 73 0.941
Used Ibuprofen
 Yes 422 74
 No 48 71 0.671
Used Codeine Ever
 Yes 291 78
 No 179 66 0.008
Physical Findings at day 3 Visit
Uterine Mass
 Yes 12 92
 No 451 74 0.199a
Uterine Mobility
 Yes 456 74
 No 8 38 0.033a
Uterine Tenderness
 None 414 73
 Mild/Moderate 53 77 0.516
Pool of Blood Present in the vagina
 Yes 164 87
 No 303 66 <.0001
Old Blood Only in the vagina
 Yes 186 73
 No 280 74 0.914
Cervical os
 Open 105 89
 Closed 362 69 <0.001
Cervical Active Bleeding
 None 233 66
 Mild or Heavy 167 80 0.002
Tissue at the cervical os
 Yes 77 91
 No 391 70 < 0.001
a
Reported Fisher’s Exact two sided P value because cell counts were less than 5 therefore Chi square test may not be valid.
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Table 2
Univariate analysis of clinical indicators for success of misoprostol treatment on day 8
Variables n Success (%) P value
Variables from Symptom Diary: After Dose 2, From day4 to day 8
Heavy Bleeding Ever
 Yes 44 39
 No 60 73 < 0.001
Passed Tissue Ever
 Yes 27 26
 No 77 70 < 0.0001
Tired Ever
 Yes 43 51
 No 61 64 0.193
Light Headed Ever
 Yes 64 53
 No 40 68 0.148
Faint Ever
 Yes 94 56
 No 10 80 0.189a
Called Doctors Ever
 Yes 88 56
 No 16 75 0.177a
Visit Doctors Ever
 Yes 97 58
 No 7 71 0.694a
Used Ibuprofen
 Yes 21 33
 No 83 65 0.008
Used Codeine Ever
 Yes 51 49
 No 53 68 0.050
Physical Findings After Dose 2, at day 8
Uterine Tenderness
 None 96 59
 Mild/Moderate 8 63 1.000a
Pool of Blood in the vagina
 Yes 22 81
 No 83 53 0.016a
Old Blood Only in the vagina
 Yes 46 74
 No 59 47 0.006
Cervical os
 Open (1) 21 62
 Closed (2) 84 58 0.766
Cervical Active Bleeding
 None 67 49
 Mild or Heavy 26 77 0.016
Tissue at the Cervical os
 Yes 16 69
 No 89 57 0.391
a
Reported Fisher’s Exact two sided P value because cell counts were less than 5 therefore Chi square test may not be valid.
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